9/23/2020 9:34:15 PM
ADC Therapeutics Announces Pricing Of Upsized Public Offering Of 6 Mln Shares At $34.00/shr
9/17/2020 7:22:08 AM
ADC Therapeutics Presents Preliminary Findings From Phase 1b
Clinical Trial Of Cami In Advanced Solid Tumors
8/18/2020 7:20:09 AM
ADC Therapeutics Q2 Net Loss $126.6 Mln Or $2.01/Shr Vs Loss $23.3 Mln Or $0.49/Shr Last Year
7/6/2020 7:32:56 AM
ADC Therapeutics: FDA Lifted Partial Clinical Hold On Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine
6/30/2020 10:43:28 AM
ADC Therapeutics Completes $267 Mln IPO
6/12/2020 2:33:20 AM
ADC Therapeutics Announces Maturing Data From LOTIS 2, A Pivotal Phase 2 Clinical Trial Of Loncastuximab Tesirine
5/21/2020 7:08:10 AM
ADC Therapeutics To Present Interim Clinical Data On Lonca At The Virtual 25th EHA25
1/10/2020 6:06:54 AM
ADC Therapeutics Names Joseph Camardo Head Of Medical Affairs
1/9/2020 6:04:23 AM
ADC Therapeutics Announces Positive Results From Pivotal Phase 2 Clinical Trial Of ADCT-402
6/4/2009 12:24:34 PM
Credit Suisse Is Increasing ADC Telecommunications Inc (ADCT) 2010 Rev. Estimate To 1.08 Billion From 1.01 Billion
6/4/2009 12:22:11 PM
Credit Suisse Is Raising ADC Telecommunications Inc (ADCT) 2009 Rev. Estimate To 1.07 Billion From 1.03 Billion
6/4/2009 12:19:55 PM
Credit Suisse Is Raising ADC Telecommunications Inc (ADCT) 2010 Estimate To 0.29 From 0.01
2/3/2009 8:27:39 AM
Credit Suisse Is Lowering ADC Telecommunications Inc (ADCT) 2009 Rev. Estimate To 1.07 Billion From 1.09 Billion